Active Biotech AB Interim report January-June 2009

(Thomson Reuters ONE) - * Laquinimod -- BRAVO Phase III trial fully enrolled* 57-57 -- explorative clinical trial initiated* RhuDex(TM) -- preclinical tests in progress* ANYARA -- Phase III trial fully enrolled* TASQ -- Phase II trial fully enrolled* ISI - target molecule for Q compounds published* Net sales of SEK 5.2 M (5.8)* Operating loss of SEK 118.5 M (loss: 104.7)* Loss after tax of SEK 118.6 M (loss: 99.3)* Loss per share for the period of SEK 2.22 (loss 2.07)* Implemented rights issue contributed approximately SEK 249 M* Number of shares at the end of the period (incl. warrants), 65,052,238 For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95 Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54 Hans Kolam CFO Tel: +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00 This report is also available at www.activebiotech.com http://hugin.info/1002/R/1332925/315776.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 06.08.2009 - 08:30 Uhr
Sprache: Deutsch
News-ID 4417
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 233 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB Interim report January-June 2009"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech